This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Comprehensive treatment protocols were developed for the trial and designed for delivery by practitioners working in routine NHS CAMHS settings. The rational for using treatment manuals as guides to therapy is that:
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The case management process is integrated through the development of a formulation which is a general construct summarising the probable relationship between the above 3 constructs. The formulation is developed as a series of prospective working hypotheses that can be tested and evaluated against subsequent progress within the therapy. BPI is delivered within this framework in up to 12 sessions, consisting of up to 8 individual and up to 4 family/parent sessions, over 20 weeks.
Therapy was delivered with the following strategies and principles being utilised throughout.
 Effective engagement, activation and problem solving.
 Diagnostic accuracy, and mental state evaluation.
 Sharing understanding and knowledge of the impairments and consequences of symptoms; the "lived experience" including effects in other settings such as school or peer relationships.
 Attention to accuracy in conducting a risk assessment and its management.
 Sharing aetiological description: defining risk and protective factors.
 A psycho-educative approach that at all points aims to help "activate" and empower, including parents and family as necessary.
 An approach that includes understanding of the role of medication, its appropriate use and how it sits within the care package  A jointly agreed, collaboratively developed, and shared, management plan  All delivered in a fashion that can help the child, young person and parents to manage and cope with their emotional expression.
Therapists, training and supervision
BPI therapists in this study were drawn from a range of professional backgrounds including mental health nursing, clinical psychology, psychiatry and mental health social work. The majority (>80%) of therapists were however psychiatrists in specialist CAMHS training as well as consultants. In the IMPACT trial to be eligible for training as a BPI therapist clinicians had to:
 Have had a minimum of 6 months supervised or independent work in a multidisciplinary child and adolescent mental health setting.
 Have already established sufficient competence and skills to be allowed to undertake independent mental health assessment and treatment of adolescents with moderate to severe depression.
BPI practitioners had basic training in BPI: reading of the manual; confirmation by the supervising clinician that they met the criteria to become a BPI therapist; attendance at a BPI training day; continued access to the BPI manual and ongoing supervision fitting in with usual local CAMHS NHS supervisory structures. The regional leads for BPI met and problem solved supervisory issues in relation to BPI on a regular basis across the IMPACT study period. 8th April 2016
Short Term Psychoanalytic Psychotherapy (STPP)
Psychoanalytic psychotherapy with children and young people is a well-established specialist treatment for emotional and developmental difficulties in childhood and adolescence, with an emerging evidence-base. [70] [71] It is one of several psychological therapies recommended by NICE as equally effective in the acute treatment of child and adolescent depression. 1 Its intellectual roots are drawn from psychoanalysis, child development, attachment theory and developmental psychopathology.
In this trial all therapists were approved as psychoanalytically trained by the Association of Child
Psychotherapists UK. The short-term model of psychoanalytic psychotherapy (STPP) used shares therapeutic principles with time-limited psychodynamic work for adults with depression for which there is now a substantial evidence-base. 2 It is a 28-session model, with parents or carers being offered up to 7 additional sessions by a separate parent worker. STPP aims to elaborate and increase the coherence of the young person's mental models of attachment relationships and thereby improve their capacity for affect regulation as well as the capacity for making and maintaining positive relationships with other. 3 The STPP method 2,3,4 draws on a long history in the UK of psychoanalytic work with depressed children and young people 74 including an unpublished manual used in an earlier clinical trial, in which short-term psychoanalytic psychotherapy for children with depression demonstrated good outcomes. 5 As with the other manuals used in the IMPACT study, the STPP manual 71 provided a guide to practice but not a recipe or a stepby-step guide, and drew on the existing skills and training of child and adolescent psychotherapists already working in the NHS.
STPP aims to elaborate and increase the coherence of the young person's mental models of attachment relationships and thereby improve their capacity for affect regulation as well as the capacity for making and maintaining positive relationships with others. When treatment is successful, it should free the young person to engage in normal adolescent development including educational attainment and independent peer group development involving a degree of separation from their primary carers. 6, 7, 8 The techniques of child and adolescent psychotherapy are primarily based on close and detailed observation of the relationship the child or young person makes with their therapist. The therapist introduces the therapeutic task to the young person as one of understanding feelings and difficulties in their life. The therapist's stance is non-judgemental and enquiring and conveys the value of understanding: the aim is to put into words conscious and unconscious thoughts and feelings. Through actions and words, the therapist attempts to convey an openness to all forms of psychic experience -current preoccupations, memories, day-dreams, nocturnal dreams and phantasies -but will be attuned specifically to evidence of unconscious phantasies which underlie the young person's relationship to self and others. This attentiveness to unconscious phenomena is specific to psychoanalytic psychotherapy, and is related to the theoretical importance attributed to these deeper less accessible layers of the mind.
With all adolescents, most particularly those with difficult early years' experiences, there is a need for the therapist to be in a state of mind characterised by availability to the reception of projected contents (anxieties, 8th April 2016 affects, uncertainties) of the adolescent's mind. The patient's experience of the therapist receiving, holding in mind, and thinking about this projected material is a central feature of the therapy. The adolescents are helped to gain ownership of previously disowned part of themselves, and are strengthened by identification with another person (i.e. the therapist) experienced as capable of making meaning in this way and thus enabling more mature thinking to take place.
The STPP therapist and/or parent worker requires an alertness to the need, at times, for active communication and liaison with other significant individuals and agencies in the adolescent's life. This may include external agencies such as school/college, youth and social services, and also mental health colleagues, including Child and Adolescent Psychiatrists, where there are issues about risk and a possible need for medication or hospitalization. Prescribing an SSRI is not a part of STPP per se but can be added and fully integrated if improvement is not judged to be occurring after 2-4 weeks as per the NICE guidelines of 2005. 12 Support for parents or carers, offered concurrently and in parallel with individual therapy for children and adolescents, is a well-established practice in the UK. There is some evidence that psychoanalytic therapy is more effective when undertaken with concurrent parent support work. 7 Parent support aims to help with parental anxieties and develop greater understanding about their relationship to their son or daughter. The duration of treatment and number of sessions prescribed is based on prior studies and clinical experience with adolescent patients.
Therapists, training and supervision
To be eligible to practice as an STPP therapist in the IMPACT study the clinician had to:
 Have undertaken a four-year postgraduate professional training, leading to membership of the Association of Child Psychotherapists (ACP) or be fourth-year trainee members of the ACP.
 Those doing parent work were individuals with at least 6 months CAMHS experience following professional training in child psychotherapy, clinical or counselling psychology, child mental health nursing, family therapy or psychiatry.
STPP training was designed and delivered on the basis that prospective STPP practitioners already have all the fundamental competencies and skills required to deliver all the components of STPP. Building upon these existing skills STPP training for IMPACT comprised: reading of the STPP manual; confirmation by the clinician that they met the criteria to become an STPP therapist; and attendance at an STPP training day.
STPP supervision by a consultant Child and Adolescent Psychotherapist was provided as part of routine practice within the CAMHS team.
Cognitive Behaviour Therapy (CBT)
Cognitive Behaviour Therapy (CBT) therapy in this trial is based on the classical form originally developed for adults with depression. This posits that emotional disorders are characterised by pervasive information processing biases which increase vulnerability to depression in the context of environmental stress, and which maintain and amplify core symptoms of depression including hopelessness, low mood, and irritability. The 8th April 2016 focus of CBT is to identify the information processing biases that maintain depression and low mood and to amend these through a process of collaborative empiricism between the therapist and client.
It was adapted for this study to include parental involvement, a large focus on engagement and an emphasis on the use of behavioural techniques. In this study CBT was manualised and incorporated adaptations for working with adolescents (as opposed to adults) including inclusion of simplified and aged appropriate cognitive techniques as well as the flexibility to take a behavioural focus if cognitive work was considered too demanding for a young person. A number of additional amendments were made including a greater focus on engagement in therapy, on building the therapeutic alliance, and on working collaboratively with parents and schools. Parents were involved in treatment sessions as indicated by the formulation and the preferences of the family. There were no separate sessions for parents.
Treatment length for CBT was a maximum of 20 sessions, delivered weekly, tapering to every 2 weeks as needed for relapse prevention, plus up to 4 family/parent sessions. Sessions were structured with an agenda set by the therapist and young person at the start of every session and out of session assignments agreed between the therapist and young person. Typically, early sessions (1-4) focused on relationship building, understanding the young person's current presentation and experience, and psycho-education, including the CBT model. A provisional formulation of the young person's difficulties, incorporating family history, key life events and transitions, recent stressors, and coping strategies was developed with the young person (and parent where relevant). Subsequently the formulation guided treatment. This included using CBT techniques to treat non depressive comorbid symptoms of anxiety, obsessions and compulsions and oppositional behaviours.
Mid-treatment focused on identifying and modifying the behavioural and cognitive processes that maintained depression and low mood for that young person. Behavioural work included activity scheduling, ratings of mastery and pleasure and reinforcement of engagement in activities. Cognitive work included identifying dysfunctional and unhelpful automatic thoughts and thought challenging using a range of techniques including behavioural experiments. Modifications to the core CBT model, such as the use of mindfulness were permitted depending on the individual formulation. The end of treatment was marked by a focus on relapse prevention.
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Typically this included a revisit to the formulation, identifying potential risk and vulnerability factors, problem solving, and building resilience. Prescribing an SSRI is not a part of CBT per se but can be added and fully integrated if improvement is not judged to be occurring after 2-4 weeks as per the NICE guidelines of 2005.
12
Therapists, training and supervision CBT therapists were NHS staff from a range of professional backgrounds including clinical and counselling psychology, nursing, and occupational therapy. They delivered CBT for depression as part of their routine clinical practice in multi-disciplinary Child and Adolescent Mental Health services.
CBT therapists had to have received specialist training in CBT, either as part of their core professional training (i.e. as a clinical psychologist) or as post qualification training (i.e. as a nurse or occupational therapist). They were eligible to be IMPACT CBT therapists if they routinely used CBT in their NHS clinical work and if they could demonstrate some pre or post qualification training in CBT.
CBT training was delivered as a one day workshop within services. It was designed as a top-up training for individuals who already had core CBT skills. The core features of the treatment manual were described and the practicalities and constraints of delivering CBT within the context of a research trial were discussed. All clinicians had copies of the CBT manual and familiarised themselves with it.
CBT supervision was provided as part of routine practice within the CAMHS team.
Prescribing of Fluoxetine during the trial
For all three arms Fluoxetine or another SSRI could be added where clinicians judged that combination therapy may accelerate the time to remission following NICE guidelines for a major depression episode in adolescents. 12 A test dose of 10 mg was given for 48 hours followed by 20 mg as a single dose. If there was no improvement within 2-4 weeks the dose can be adjusted upwards to 60 mg maximum. 
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CPPS-ER)
The CPPS is a measure that assesses the degree to which a therapist uses techniques of psychodynamicinterpersonal (PI) and/or cognitive behavioural psychotherapy (CB) in an entire psychotherapy session. 1 Developed from an extensive empirical review of the comparative psychotherapy process literature, all items are rated on a seven-point Likert Scale, ranging from 0 ("not at all characteristic"), 2 ("somewhat characteristic"), 4 ("characteristic"), to 6 ("extremely characteristic"). 1 The 20-item measure includes ten PI items and ten CB items, forming two distinct sub-scales. The psychometric properties of the CPPS have been well established in psychotherapy with adults. 1 Internal consistency of both scales has been good to excellent: Cronbach's α of ·82 to ·92 for the PI scale and ·75 to ·94 for the CB scale. 2, 3 Inter-rater reliability is reported as rating from good through to excellent (ICC 0·6 to 0·75).
2,4
Brief Psychological Intervention Scale (BPI-S)
The BPI-S is a new scale, developed specifically for use in this study to assess treatment adherence to BPI. The 18 key components of the BPI manualised treatment were identified using expert consensus in the IMPACT team. A pilot investigation conducted by the BPI experts used a sample of five tapes to develop the adherence scale. Following this phase the measure was operationalised as an eight-item measure with three 'core' and five 'general' items, rated as a Likert Scale (0 -no evidence, 1 -passing evidence, 2 -some evidence, to 3 -clear evidence).
The three core items are: (i) Activation and problem solving; (ii) Interpersonal effectiveness; and (iii) Attention to mental state-current presentation or diagnosis. The five general items are: (i) Attention to vulnerability and protective factors, (ii) Psycho-education; (iii) Setting case management within a BPI framework; (iv) Attending to the social context of the patient; and (v) Making effort to help the patient manage their emotional expression. These eight items were chosen to (a) capture important treatment principles (relevance), based on the BPI manual; and (b) cover all relevant treatment principles (comprehensiveness), as outlined in the BPI manual.
For each item, a score of two or more was considered an adequate level of adherence. Overall, a BPI therapy session was judged to be 'adherent' if: i.
At least two out of three 'core' items were rated as 2 or above ii. And a total of at least four out of the eight items were rated as 2 or above.
When this revised standard was applied to the five taped sessions previously rated, 100% agreement was obtained between the experts who rated four sessions as adherent and one session as not adherent.
Training for five independent raters was completed over two days. The raters were all trained in BPI and experienced senior clinicians with medical and psychiatric qualifications, and achieved high levels of inter-rater reliability (>80%) by the end of the training. Feedback from the raters during the training process indicated high levels of face validity indicated by good comprehension of the BPI adherence scale and an understanding of the rating measure and procedure. Each session was watched in its entirety, and then rated by the two judges independently; but raters were not blind to the treatment arm, as only BPI sessions were rated using the BPI-S. 
Study Design
Originally it was proposed that the trial will run in six CAMH clinics in each of three centres, giving 18 clinics with a minimum of one therapist for each treatment modality in each clinic and ten patients per treatment modality recruited in each clinic. This gives a total sample size of 540.
The ADAPT trial gave an SD of 14·6 at 28 weeks follow-up and correlation between baseline and follow-up of 0·41 for MFQ, proposed primary outcome of this study. We have assumed five points on the MFQ to be the minimum clinically important difference. This is approximately 25% of the change in the MFQ scale from baseline to 28 weeks. It is equivalent to a one point improvement on five of the 34 items of the scale. It is a standardize effect size of 0·34 (small to medium) and corresponds to non-overlap between treatments of approximately 25% (Cohen, 1988) . Table 1 below gives estimates of power for Superiority, Non-Inferiority, and Equivalence designs for an intra-therapist correlation coefficient of 0·0, 0·025, or 0·05. Provided that the intracluster correlation is less than 0·025 a superiority analysis comparing CBT with STPP will have a power of over 80%. By virtue of the increased sample size specialist comparisons of the specialist treatments (CBT and STPP) with treatment as usual (SCC) will have substantial power. These power calculations assume a cross-sectional analysis, but statistical analysis will be based on longitudinal data using a linear mixed effects model (LME, see Section 8·2). Use of such a model will increase the power of the statistical analysis as data is in effect shared across follow-up time-points. This power calculation assumed a 90% follow-up as 92% follow-up at 28 weeks was achieved in ADAPT.
Allocation to treatment group was by minimisation controlling for severity (defined by MFQ score), sex, age, and recruiting region.
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2·1 Statistical Hypotheses
The study was designed with a two level hypothesis: i) Both CBT and STPP will show superiority effects compared to BPI in the primary outcomes at 52 and 86 weeks; ii) CBT will show non-inferiority effects to STPP at 52 weeks; iii) STPP will show superiority effects compared to CBT at 86 weeks. 
3·2 Secondary outcome measures
Along with the primary outcome, the secondary outcome measures are shown in the last column of Table 2 by frequency of collection and type of report. All are assumed to be continuous variables.
3·3 Hierarchy of young person versus parent reporting on various scales
When a young person and the parent both complete a particular questionnaire then the young person's data will form the basis of the main inference. The results from the parent will be supplementary.
Data analyses
Data analyses will be carried out by a statistician based in Biostatistics, Institute of Population Health, Manchester University, under the supervision of the trial statistician (CR) in conjunction with the IMPACT trial coordinator and trial centre in Cambridge. Economic data analyses will be carried out by a health economist based in the Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, Kings College London, under the supervision of the trial economist (SB).
Data Sources
5·1 Pre randomisation data
Data are required for completion of the CONSORT diagram pre randomisation. These include:  Numbers of potential participants assessed  Numbers excluded after initial assessment by reason  Numbers invited to baseline research interview  Numbers excluded after baseline research interview by reason  Numbers consenting and randomised by treatment arm.
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5·2 Demographic data and patient characteristics prior to randomisation of randomised patients
The information collected at baseline consisted of basic demographic data (gender, age, twin, adopted/fostered, complications with pregnancy/labour/delivery, ethnicity, living arrangements, education, family employment) and clinical data (current medical problems, current medication of subject and other family member currently or in the past suffering any medical, emotional, or behavioural problems), plus the standard schedules as shown in Table 2 .
5·3 Therapist/Care Provider and Treatment data
As suggested in the CONSORT guidance extension for trials of non-pharmacological interventions, information will be gathered regarding the characteristics of all therapists and care providers for each intervention. A statistical summary of this data will be prepared.
For each patient the intended therapist assigned at randomisation will be recorded along with the number of sessions attended.
The following minimum data will be collected for each trial therapy session (SCC, CBT, STPP):  Therapist id  Type of therapy delivered  Individuals present in session This will be aggregated to determine the number and type of therapy sessions received from each therapist.
A Kaplan-Meier plot and the associated log-rank test will be presented for time from randomisation to start of trial therapy and time to completion of trial therapy by a) treatment arm and b) by regional research centre (EA, NL, NW). Summary statistics will be provided for duration of therapy by treatment arm.
5·4 Follow-up Assessments
The follow-up schedule is shown in Table 2 .
Handling Missing Data and Slotting of Assessments
6·1 Item Non-response in Scale Measures
For questionnaire instruments, item non-response will be dealt with using a pro-rating strategy. Provided that at least 50% of items are available the observed total (for the completed items) and the number of items completed will be used to calculate an adjusted total as follows:
Adjusted total = Observed total * Total number of items in scale/Number of items completed Note, this is equivalent to replacing the missing item by the average of available data for that dimension. The extent of pro-rata estimation will be reported for each scale for each treatment arm.
The NEO-FFI with five subscales and DSC with two subscales (global and affective) will have each subscale pro-rated and analysed separately.
6·2 Missing baseline covariate data
Subjects will not be excluded from outcome analyses due to missing baseline data. Where baseline covariate data (current not lifetime) cannot be obtained across different questionnaires, simple imputation (White & Thompson, 2005) which is based on multiple regression will be used. The following covariates will be used (see Section 8·2): region, comorbid behaviour disorders (CD+ODD), all anxiety disorders combined, SSRI use at baseline, age at randomisation, and sex. In addition baseline severity (MFQ score) will also be used. Substitution or imputation will not be used for post-baseline outcomes (see Section 8·3 for reasons).
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6·3 Slotting of assessment measures
In RCT studies there is often a delay in starting the therapy post randomisation and the visits (research assessments) are scheduled relative to the start of therapy rather than from time since randomisation. To provide summary statistics we need to assign each actual assessment to a target assessment week based on pre-defined intervals from time since randomisation. The assessment will be assigned to one of the following scheduled visit weeks based on the interval it falls into for the time (in weeks) from randomisation: Note, these bands may have to be modified when the data is inspected. To avoid bias this will be carried out blind to outcome scores by calculating summary statistics on the completeness of the primary outcome and will take account of the results of analyses on time to start and completion of trial therapies.
Scheduled
If, for a given assessment window, there is more than one measurement in the band then the measurement nearest to the week from randomisation will be used for descriptive statistics.
Descriptive Analyses of randomised patients
7·1 Baseline Characteristics
Patients in the three treatment groups (SCC, CBT, STPP) will be described separately with respect to the characteristics given in Section 5·2.
Numbers (with percentages) for binary and categorical variables, and ordered categories plus means, standard deviation, median plus minimum and maximum values for continuous variables will be presented. Consistent with CONSORT guidance there will be no tests of statistical significance or confidence intervals for differences between randomised groups for any baseline variable.
All baseline measurement scales will be summarised separately for adolescent and parent responses, by treatment arm.
7·2 Follow-up
All measurement scales in Table 2 taken during follow-up will be summarised separately for adolescent and parents, by visit and each treatment arm. Note, the assignment of data to a specific assessment visit will use slotting as described in Section 6·3.
7·3 Missing follow-up data
For the primary outcome measure (MFQ) the frequencies (with percentages) of patient losses to follow-up at 6, 12, 36, 52, and 86 weeks after randomisation will be reported and compared between arms. For each subject, the provision of a measurement at each time point will be based on the slotting procedure given in Section 6·3.
Treatment arm and selected baseline characteristics (see Section 5·2) of subjects providing an adolescent outcome measure at the week 6 visit and those with missing data will be compared using a logistic regression model. Similarly, separate logistic regression models will be used to investigate patterns of failure to provide outcome measures at the later follow-up weeks. These analyses will be used to develop an understanding of the missing data mechanism. These models will be repeated for the primary parent MFQ measure. The reasons for end of treatment and study discontinuation will be tabulated by treatment arm. 
7·4 Quality Control of Measures
Observer Reliability between and within research sites Intra and inter observer reliability will be considered using graphical methods and relevant summary statistics including intra-class correlation coefficients and kappa coefficients.
Statistical analysis of outcome comparing treatments
Extensive data cleaning of outcome and baseline data will be conducted without the treatment group allocations attached to the dataset. Results of these preliminary analyses will be reviewed by the trial research team to identify data errors and carry out preliminary checks regarding distributional assumptions prior to linking the treatment allocation to the follow-up data.
The analyses comparing treatments will be conducted applying the principle of intention to treat (ITT). No interim analyses of outcome data will be carried out unless specifically requested by the trial data monitoring and ethics committee.
8·1 Statistical inference between treatments
Within the protocol we considered both superiority and non-inferiority as potentially relevant hypotheses. The following hypotheses are stated in the protocol: i) CBT will show superiority effects compared to SCC in the primary outcomes at 52 and 86 weeks ii) STPP will show superiority effects compared to SCC in the primary outcomes at 52 and 86 weeks iii) CBT will show non inferiority effects to STPP at 52 weeks iv) STPP will show superiority effects compared to CBT at 86 weeks.
The hypotheses will be addressed using a linear mixed models analysis.
8·2 Treatment Effect Estimation for the Primary Outcome and other Continuous Outcome Measures
The intervention may influence outcome in two ways. Firstly, there may be a faster rate of recovery by 36 weeks and/or reduced clinically meaningful symptom recurrence between weeks 36 to 86 in one group than the other. Differential changes in symptoms over time can be estimated using a time with intervention group interaction. Secondly, there may be a systematic difference between intervention groups during follow-up, which is measured by a main effect. The statistical analysis of the primary outcome measure (MFQ) and the secondary continuous measures (see Table 2 ) will estimate the treatment effect using linear mixed effects models (LME, also know as random effects or random coefficient models). For all models, time (from randomisation considered as a continuous variable) will be centred based on the available data for the particular analysis being undertaken.
Because the aim of this study is to establish the longer term benefits of therapy we will consider only data over the post-treatment period for the primary analyses. All measures from week 36 onwards will be used for the statistical analyses for this purpose. By using data from week 36 onwards this should yield up to three measures per subject. This and the fact that time is continuous rather than discrete will reduce the potential for model identifiability problems given the number of random effects, time points and interaction terms.
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Models with and without a time with treatment interaction Each model will adjust for baseline values of the outcome under consideration and the pre-specified prognostic variables as shown in Table 3 : Co-morbid behaviour disorders (i.e., a diagnosis of oppositional defiant disorder or conduct disorder) and all anxiety disorders combined + Other baseline: see MFQ outcome SR= Self-report *These covariates will be used in all lme models + For these two disorders a binary variable will be created for absent (coded as 0) versus a diagnosis of "Yes" or a "high clinical index" (coded as 1).
Models will also include a subject level random intercept and correlated random coefficient for time. In addition, therapist will be included as a random effect subject to model fitting constraints. First, a model with a time with intervention group interaction will be fitted. If there is a significant treatment by time interaction, inference for the interaction will be reported and separate adjusted treatment effects for the three pairs of treatments will be estimated for 52 and 86 weeks from the model. The hypothesis of noninferiority of CBT relative to STPP at 52 weeks will be addressed by considering the 95% confidence interval of the treatment effect.
If the interaction between time and treatments is not significant, this term will be omitted from the model. Adjusted treatment effects will be estimated and tested using this simplified model. Non-inferiority will be considered using the 95% confidence interval of the treatment effect. To assess the treatment effect while receiving therapy, random intercept LME models will be fitted to data prior to week 36 post randomisation, made up mostly of notional week 6 and 12 assessment data.
8·3 LME Inference and missing data
Of note, by using maximum likelihood for these models, "Missing At Random" is assumed for drop-out i.e., missing outcome data is conditional on observed data. Under this assumption it is assumed that future behaviour, given the past, is the same for all, whether a subject drops out or not. This allows distributional information to be "borrowed" from those who remain on the trial and applied to those who drop-out given they have the same covariate set up until the time of dropout. Therefore, the estimand of the treatment effect is what would be seen if all subjects had remained on the study until the end.
8·4 LME Model Diagnostics
Normal probability plots will be used to check distributional assumptions of the model for residuals of within and between subject variance terms. Where there is evidence of non-normality outcome data may be transformed.
8·5 Longitudinal Models for the parent MFQ and other Continuous Outcome Measures
The analysis of the parent data and the secondary outcome measures will be essentially the same as the primary analyses of the adolescent data.
8·6 Models for binary and ordinal outcome data
Binary data will be analysed using longitudinal logistic regression and ordered categorical secondary outcome measures such as the CGI scale will be analysed using an ordinal logistic regression model with random intercept and gradient terms on the log-odds scale.
Further Analyses
9·1 Adherence to therapy
Summary statistics on the number of trial therapy sessions attended by each subject will be tabulated by arm. A frequency distribution of number of sessions will also be presented by arm. In addition, the percentage of target total sessions will be summarised by arm. Based on input from specialists, a binary variable for adherence is defined as follows for the three modalities: STPP: Eight sessions is considered as the minimum therapeutic dose: thus adherence = 0 when seven or fewer sessions in total are completed, otherwise adherence = 1.
CBT: Six sessions is considered as the minimum therapeutic dose: thus adherence = 0 when five or fewer sessions are completed, otherwise adherence = 1.
BPI: Three sessions is considered as the minimum therapeutic dose: thus adherence = 0 when two or fewer sessions are completed, otherwise adherence = 1.
Adherence will be summarised by arm and this may be used in a secondary causal analysis of treatment effects which will be investigated separately from the main statistical analysis following a proposed discussion of causal pathways. Analyses will estimate the propensity to receive/adhere to treatment, accounting for SSRI usage at baseline as a dichotomous variable. 8th April 2016
9·2 Moderator Analyses
The following are the pre-specified moderators of treatment which will be investigated, one at a time, to determine whether they interact statistically with therapy group based on MFQ outcome data over the short term (i.e. >0 and < 36 weeks post randomisation) analysed using linear random intercept models:
 MFQ score at baseline  Age at randomisation  Sex  Region  SSRI prescribing at baseline Based on the MFQ outcome data from week 36 onwards the same treatment interactions will be tested using random effects (intercept and slope) models.
In addition, an interaction between MFQ score and SSRI usage at baseline will be examined.
Economic evaluation
10·1 Perspective
In the first instance the economic evaluation will take a service perspective, which will include the use of all hospital, community health, costs in addition to mainstream education and social services. Secondly, we will undertake analyses from a societal perspective, which in addition to the service costs will include the out of pocket costs of travel to treatment that fall to carers and any productivity losses for the study participant or their carer as a result of illness.
10·2 Calculation of total costs
For each piece of service use information collected in the CA-SUS, a unit cost (for example a cost per hour with a professional, a cost per inpatient night, a cost per unit of a drug) will be applied and the total costs calculated. The total cost per participant is calculated by summing all costs. All unit costs will be for the financial year 2012-2013. Costs between 52 and 86 weeks will be discounted at a rate of 3·5% because cost-effectiveness results should reflect the present value of costs and benefits, as recommended by the National Institute for Health and Clinical Excellence (NICE) 2013. Sensitivity analysis using rates of 1·5% will also be presented in additional analyses.
All NHS hospital contacts will be costed using NHS reference costs (Department of Health 2011). Unit costs of community health and social services will be taken from national publications (Curtis 2011 ) and education costs from government published statistics (https://www.gov.uk/government/statistics/la-and-school-expenditurefinancial-year-2012-to-2013). Medications will be costed using information in the British National Formulary (British Medical Association and Royal Pharmaceutical Society of Great Britain 2010). Contacts with criminal justice sector services using available data from published sources (e.g. HM Prison Service 2009). Where necessary, costs will be inflated to 2012-2013 rates using the Hospital and Community Health Services inflation indices or the Retail Price inflation indices, as appropriate (Curtis 2011 ).
The cost of the CBT, STPP, and SCC interventions will be calculated on the basis of the salary of the therapist plus overhead expenses (administrative, managerial, and capital). Calculation of the indirect time, including preparation and supervision of therapists, will be based on information provided by the trial therapists on the ratio of direct face-to-face contact compared with other intervention-related activities using the bottom-up approach (Drummond et al. 2005 ) used in similar research (Byford et al. 2007 ) to generate a cost per hour with each study therapist and clinician. Sensitivity analyses will vary the assumptions used in generating the intervention unit costs to investigate the impact of low and high cost estimates on the results of the study. Productivity losses will be calculated for the adolescent (if they are in employment) and the parent or carer using the human capital approach, which involves multiplying the individual's salary by reported days off work due to illness.
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10·3 Calculation of QALYs
QALYs will be calculated on the basis of the EuroQol EQ-5D health state classification instrument which has five domains: mobility; self-care; usual activities; pain/discomfort; and anxiety/depression. For each domain the respondent chooses one of three levels of functioning, good to poor. The three levels for each of the five domains are used to define 243 health states (Glick et al. 2007 ). The health states will then be given a utility score using responses from a representative sample of adults in the UK (Dolan et al. 1995) . QALYs in the second year will be discounted at a rate of 3·5%, as recommended by NICE (National Institute for Health and Clinical Excellence 2013). QALYs will be calculated as the area under the curve as defined by the utility values at baseline, six, 12, 36, 52, and 86 weeks follow-up and it will be assumed that changes in utility score over time will follow a linear path (Richardson and Manca 2004 ).
10·4 Service use
Differences in the use of services between randomised groups will be compared descriptively. No statistical comparisons will be made.
10·5 Costs
Total cost per participant over follow-up will be calculated and analysed for both a service and a societal perspective. Although costs are not expected to be normally distributed, analysis will compare mean costs using standard t-tests/analysis of co-variance with covariates as described in Section 8·2. The robustness of the parametric tests will be confirmed using non-parametric, bias-corrected bootstrapping (Barber & Thompson, 2000) . The following comparisons will be made:
1. CBT v BPI at 52 and 86 weeks 2. STPP v BPI at 52 and 86 weeks 3. CBT v STPP v BPI at 52 and 86 weeks
10·6 Cost-utility analysis
Cost-utility analysis will be undertaken using quality adjusted life years (QALYs) calculated from the EQ-5D as the measure of effect. Cost-utility will be assessed through the calculation of incremental cost-effectiveness ratios (ICERs) -the ratio of the additional cost of one intervention compared with another over the additional effects of one intervention over another. The following primary cost-utility analyses will be carried out using a service perspective: 1. CBT vs BPI at 86 weeks 2. STPP vs BPI at 86 weeks 3. A three-way analysis which will involve pair-wise comparisons between CBT, STPP, and BPI and a three-way comparison at the 86-week follow-up. When more than two strategies are compared, ICERs are calculated using rules of dominance and extended dominance (Johannesson & Weinstein, 1993 ). Strategies will be ranked by cost, from the least expensive to the most expensive, and if a strategy is more expensive and less effective than the previous strategy, it is said to be dominated and is excluded from the calculation of ICERs. This process compares strategies in terms of observed differences in costs and effects, regardless of the statistical significance of the difference.
In addition, a secondary analysis will make the same comparisons using a societal perspective and also using data from the 52 weeks follow-up.
Uncertainty around the costs and effectiveness estimates will be represented by cost-effectiveness acceptability curves, which will be calculated using the net benefit approach (Briggs, 2001). Net benefits for the sample using values for λ (willingness to pay for an additional QALY) ranging from £0 to a maximum value of £50,000 will be calculated. A bootstrap replication of 5000 means for each net benefit estimate will be created, adjusted for baseline covariates outlined in Section 8·2.
The proportion of these replications that are greater than zero will indicate the probability that the intervention is cost-effective for each value of λ. Plotting these probabilities on a graph creates a cost-effectiveness 8th April 2016 acceptability curve, which depicts graphically the probability that the estimated cost-effectiveness ratio falls below the specified willingness to pay values (Van Hout et al., 1994).
10·7 Sensitivity analyses
A number of one-way sensitivity analyses will be undertaken to test the robustness of the results to the assumptions made in the economic evaluation. These will include, but will not be limited to:
• Variation of the cost of the interventions, dependent on seniority of therapists, time in direct contact with patients and other assumptions.
• Variation in the rate used for discounting of costs and outcomes in the second year to 1·5% as recommended by NICE (2013).
Potential Additional Analyses Mediator Analyses
Analysis of treatment mediators will depend on there being evidence of a treatment effect and will therefore be part of a later exploratory analysis. The effect of treatment on the mediators will be investigated separately from the main statistical analysis following the proposed discussion of causal pathways. The proposed mediators are:
STPP:
STPP involves reflective and dynamic processes directly with the patient focussing on potential underlying unconscious abnormalities stemming from experience dependent learning. Parent support is a key element in this therapy and we hypothesise that improvements in parent well-being will mediate the efficacy of STPP by 86 weeks. This will be expressed as: Lower Global Severity Index scores of the SCL-90 over the course of treatment will be associated with better response to STPP revealed as lower self reported depression scores by 86 weeks.
CBT:
CBT involves a very clear focus on current abnormalities and distortions of thinking processes and their ruminative style that serves to maintain and potentially amplify the pathological cognitive reasoning about the self, the future, and the world. We hypothesise that self-reported ruminations about negative cognitions will mediate the efficacy of CBT by 86 weeks. This will be expressed as: Lower self reported total rumination score over the course of treatment will be associated with a better response to CBT revealed as lower self reported depression scores by 86 weeks.
BPI:
BPI is a pragmatic treatment involving here and now advice and support to aid understanding of illness and remedy clear-cut maladaptive behaviours in the environment such as social withdrawal and solitariness. We hypothesise that reducing solitariness and increasing behavioural sociability through a focus on well-being will mediate the efficacy of SCC by 86 weeks. This will be expressed as: High friendship scores over the course of the treatment will be associated with a better response to SCC revealed as lower self-report depression scores by 86 weeks.
8th
Addendum to IMPACT SAP (31st March 2016)
Section 1 and throughout document Replace specialist clinical care (SCC) with the term brief psychological intervention (BPI). Section 6.2 The SSRI covariate used for imputation and analyses was "SSRI prescribed before trial entry" (where if missing information then it was assumed not to be prescribed) and not "SSRI use at baseline". Section 6.3 The time of assessment caused some duplication in the slotting procedure where if more than one measurement was assigned to a band then only the nearest to the week from randomisation was to be used for the summary statistics. As the summary statistics from this approach were difficult to interpret we adopted the standard approach of reporting by researcher assessment instead. Section 7.2 Only the primary and secondary outcome measurement scales were summarised. Behaviours checklist (BC) is also known as the Antisocial Behaviours questionnaire (ABQ). Since the distribution of ABQ total score was highly skewed with the standard deviation larger than the mean at many time-points and medians of zero at weeks 52 and 86 for each group we considered ABQ as a binary outcome coded as one if the ABQ score was ≥1. Section 8.2 Because MFQ and RCMAS are correlated the latter was omitted where both were originally listed as baseline covariates in an outcome model (except for the RCMAS outcome where MFQ was dropped). The covariates in Table 3 of the SAP were replaced by the ones shown in Table 1 of this Addendum with ABQ entered on the 3 point scale. The SAP states: "First, a model with a time with intervention group interaction will be fitted. If there is a significant treatment by time interaction, inference for the interaction will be reported and separate adjusted treatment effects for the three pairs of treatments will be estimated for 52 and 86 weeks from the model. The hypothesis of noninferiority of CBT relative to STPP at 52 weeks will be addressed by considering the 95% confidence interval of the treatment effect."
Based on these interaction models the marginal effect of treatment was estimated at 36, 52 weeks and 86 weeks post randomisation for the following two comparisons rather than three to match the protocol hypotheses:
(i) STPP against CBT and (ii) (CBT and STPP) against BPI Note, the sample size calculation used a significance level of 2.5% to allow for this multiplicity. A Bonferroni correction was not applied to the p-values, but it is suggested that readers use a 2.5% significance level to maintain the family-wise 5% significance level at a particular point of assessment. Section 9.1 Adherence is now redefined as therapeutic dose. For STPP this was changed from ≥8 to ≥6 sessions based on consultation with experts in this therapy field.
Section 9.2
Following detailed discussion between the PI's the original list of moderators were replaced by the following as they were deemed relevant: Hypotheses for the DEQ at baseline: 1) Elevated relatedness/dependent scores will be associated with a relatively better response in the STPP group compared to BPI or CBT groups.
2) Elevated self-critical/identity scores will be associated with a relatively better response in the CBT group compared to BPI or STPP groups.
Hypotheses for the RRS at baseline 1) Higher scores will show a better treatment response in the CBT compared to the BPI and STPP arms.
Additional Analyses not specified in the SAP
In order to gain a better understanding of patterns over time in diagnosis, medication prescription and adverse events the following were undertaken. The results are presented in the HTA report. 1. We investigated change over time using GEE longitudinal analyses for Unipolar major depressive disorder (MDD) and MFQ total score >25 outcomes. The analysis of ABQ was changed from an mixed model to GEE since the data was not normally distributed. The SSRI covariate used for imputation and analyses was "SSRI prescribed before trial entry" (where if missing information then it was assumed not to be prescribed) and not "SSRI use at baseline". Section 6.3 The time of assessment caused some duplication in the slotting procedure where if more than one measurement was assigned to a band then only the nearest to the week from randomisation was to be used for the summary statistics. As the summary statistics from this approach were difficult to interpret we adopted the standard approach of reporting by researcher assessment instead. Section 7.2 Only the primary and secondary outcome measurement scales were summarised. Behaviours checklist (BC) is also known as the Antisocial Behaviours questionnaire (ABQ). Since the distribution of ABQ total score was highly skewed with the standard deviation larger than the mean at many time-points and medians of zero at weeks 52 and 86 for each group we considered ABQ as a binary outcome coded as one if the ABQ score was ≥1. Table 2 Replace 'EQ-5D: EuroQol measure of health-related quality of life' with 'EQ-5D-3L: EuroQol measure of health-related quality of life (three level version)'. This is for clarity given the development of the new EQ-5D-5L (five level version). Section 8.2 Because MFQ and RCMAS are correlated the latter was omitted where both were originally listed as baseline covariates in an outcome model (except for the RCMAS outcome where MFQ was dropped). The covariates in Table 3 of the SAP were replaced by the ones shown in Table 1 of this Addendum with ABQ entered on the 3 point scale.
The SAP states: "First, a model with a time with intervention group interaction will be fitted. If there is a significant treatment by time interaction, inference for the interaction will be reported and separate adjusted treatment effects for the three pairs of treatments will be estimated for 52 and 86 weeks from the model. The hypothesis of noninferiority of CBT relative to STPP at 52 weeks will be addressed by considering the 95% confidence interval of the treatment effect."
Based on these interaction models the marginal effect of treatment was estimated at 36, 52 weeks and 86 weeks post randomisation for the following two comparisons rather than three to match the protocol hypotheses: (iii) STPP against CBT and (iv) (CBT and STPP) against BPI Note, the sample size calculation used a significance level of 2.5% to allow for this multiplicity. A Bonferroni correction was not applied to the p-values, but it is suggested that readers use a 2.5% significance level to maintain the family-wise 5% significance level at a particular point of assessment. Section 9.1 Adherence is now redefined as therapeutic dose. For STPP this was changed from ≥8 to ≥6 sessions based on consultation with experts in this therapy field. Section 9.2 Following detailed discussion between the PI's the original list of moderators were replaced by the following as they were deemed relevant: Hypotheses for the DEQ at baseline: 1) Elevated relatedness/dependent scores will be associated with a relatively better response in the STPP group compared to BPI or CBT groups. 2) Elevated self-critical/identity scores will be associated with a relatively better response in the CBT group compared to BPI or STPP groups.
Hypotheses for the RRS at baseline 1) Higher scores will show a better treatment response in the CBT compared to the BPI and STPP arms. Section 10.1 Replace section with the following to match with the perspective as originally planned and described in the published protocol: 'The economic evaluation will take a societal perspective, including the use 8th April 2016 of all health, social care, education and criminal justice sector resources plus family costs in the form of travel to trial intervention sessions and productivity losses of the primary carer resulting from their child's illness.' Section 10.2 Remove 'Sensitivity analysis using rates of 1.5% will also be presented in additional analyses' and 'Sensitivity analyses will vary the assumptions used in generating the intervention unit costs to investigate the impact of low and high cost estimates on the results of the study'. Sensitivity analyses focus on key areas of uncertainty in an economic evaluation, which cannot always be predicted in advance. Actual sensitivity analyses undertaken are described in full in the 'Additional analyses not specified in the SAP' below. Section 10.5 Remove '52 weeks' from all comparisons in line with what was originally planned and described in the published protocol. Analyses at 52 weeks were discussed during the course of the trial, but final agreement was to stick to the original plan. Section 10.6 A further comparison was added between CBT and STPP, in line with the clinical comparisons undertaken. Section 10.6 Remove sentence 'In addition, a secondary analysis will make the same comparisons using a societal perspective and also using data from the 52 weeks follow-up.' This is no longer relevant given the removal of analyses at 52 weeks noted above. Section 10.7 This section is removed in its entirety. As noted above, sensitivity analyses focus on key areas of uncertainty in an economic evaluation, which cannot always be predicted in advance. Actual sensitivity analyses undertaken are described in full in the 'Additional analyses not specified in the SAP' below.
Additional Analyses not specified in the SAP In order to gain a better understanding of patterns over time in diagnosis, medication prescription and adverse events the following were undertaken. The results are presented in the HTA report.
4. We investigated change over time using GEE longitudinal analyses for Unipolar major depressive disorder (MDD) and MFQ total score >25 outcomes. The analysis of ABQ was changed from an mixed model to GEE since the data was not normally distributed. 5. Summaries on SSRI prescription prior to trial entry and also during follow-up overall and also split by <36 weeks and ≥36 weeks post randomisation to match the two analyses time periods were provided. 6. Adverse event reporting.
As noted above, sensitivity analyses undertaken on the economic data are hard to predict in advance as they are dependent on the assumptions made in the costing and analysis of the economic data. The following sensitivity analyses were carried out to test the robustness of the assumptions made:
1. The cost of sessions offered but not attended was explored by increasing the cost from the assumption of zero applied in the main analysis (which assumes professionals are able to make use of the time available to undertake alternative tasks) to 50% of the cost of a session (which assumes professionals make some use of the time available, but not all). Data were calculated as the number of sessions offered minus the number of sessions attended, which may not be exactly equivalent to the number of DNAs (did not attend) as sessions may have been offered but cancelled or rearranged. This analysis should therefore be interpreted with caution. 2. The impact of missing data was considered using multiple imputation of missing values. 3. Due to the variation in the timing of follow-up, cost per week was calculated and analysed, in addition to total cost over 86-weeks.
Appendix ii (continued) Additional Results From the Analyses
Symptom Characteristics of young people entering the trial Table A1 gives the prevalence of concurrent depressive symptoms from the K-SADS-PL. The most prevalent symptom was sleep disturbance (92%) followed by depressed mood (84%). The mean number of symptoms was 8·4 for the BPI group, 8·7 for CBT, and 8·3 for STPP. Recent suicide attempts refer current major depression episode. Lifetime suicide attempts refer to all lifetime except current episode. Table A2 gives a detailed breakdown of co-morbid psychiatric diagnoses recorded in the baseline K-SADS-PL by treatment group. A total of 225 (48%) were concurrently comorbid for at least one other psychiatric disorder. Of these 134 (29%) and 60 (13%) had one and two comorbidities, respectively. The maximum number of comorbidities was five in the BPI group and four in the other two groups. Overall, the most frequent comorbid diagnoses were generalised anxiety disorder and social phobia. There were no marked differences between the three treatment groups in these characteristics. 
Appendix iii Economic evaluation methods and results
Aim
The aim of the economic evaluation was to investigate the cost-effectiveness of psychological treatments for adolescent depression and in particular to determine whether the additional cost of the two specialist treatments, CBT and STPP, can be justified by improvements in effectiveness and/or decreased use of health and social care services compared to BPI by 86 weeks follow up.
Perspective
The a priori perspective of the economic evaluation was societal, including the use of all health, social care, education and criminal justice sector resources plus family costs in the form of travel to trial intervention sessions and productivity losses of the primary carer resulting from their child's illness. However, criminal justice, travel costs and productivity losses were not found to be relevant to this population, being very low, and were excluded from the analysis.
Method of economic evaluation
The primary economic analysis was a cost-effectiveness analysis with outcomes expressed as quality adjusted life years (QALYs), as recommended by NICE.
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Calculation of costs
The process of calculating costs was separated into the identification, measurement and valuation of relevant resources.
Identification of resources
Relevant resources were identified based on the results of previous studies in adolescent depression and in discussion with study clinicians and patient representatives. 7 Resource use was collected in the following domains:
Delivery of the BPI, CBT and STPP interventions Use of NHS secondary care services  Inpatient stays (mental health and all medical specialties)  Outpatient appointments (mental health and all medical specialties)  Accident and emergency attendances Use of NHS primary care services  General practitioner (in surgery, at home, and by telephone)  Community nurse (e.g. practice nurse, district nurse, health visitor, midwife)  Community paediatrician  Community mental health service  Community medical professional e.g. physiotherapist  School based mental health and medical professionals Use of medication in the following areas  Antidepressants  Sleeping tablets  Mood stabilisers/antipsychotics Use of social care and education sector services  Foster care and residential care  Staffed accommodation e.g. hostel  Social worker  Specialist education facilities  Education psychologist  Family support worker  Youth worker  Youth offending team worker
Measurement of resources
Trial interventions
The trial therapists recorded details of attendance and non-attendance at treatment sessions, and duration of treatment sessions for each study participant throughout the trial.
Other health, social care and education sector services Data on use of all other services included in the study perspective were collected using the Child and Adolescent Service Use Schedule. The CA-SUS was developed using data from several child and adolescent mental health trials and was further modified and successfully employed in a previous trial in adolescent depression. 7 The CA-SUS was completed with participants and family members in interview with a researcher at baseline and at the 6, 12, 36, 52 and 86 week follow-up interviews. At baseline, information covered the previous three months. At each of the follow-up interviews, service use since the previous interview was recorded; in this way, the entire period from baseline to final follow-up was covered. The CA-SUS asks participants for the number and duration of contacts with various services and professionals.
Valuation of resources
To calculate the total cost of the resources used by each study participant, a unit cost was applied to each resource use item. All unit costs were for the financial year 2011/12, uprated, where necessary, using the Hospital and Community Health Services Index. 8 Costs in the second year were discounted at a rate of 3·5% as recommended by NICE. 6 All unit costs are summarised in Table A10 . 
Trial treatments
Treatment sessions were costed on the basis of the profession and grade of the therapist that delivered each session for each trial participant. The length of the treatment sessions was extracted from the average duration of treatment recorded in the session record forms. Average duration of sessions was 45 minutes for BPI, 50 minutes for STPP, and 55 minutes for CBT. For the base case analysis, only the costs of the sessions that the young person attended were included. This assumption was employed because of an understanding that clinicians are usually able to do something else during the time freed up by missed appointments. In a sensitivity analysis, an estimate of the cost of the sessions that were offered but not attended was included. The data for this analysis came from the records held by the trial therapists and are the closest data to non-attendance available. The rate of non-attended sessions was included at 50% of the cost of a full session, which assumes professionals make some use of the time available, but not all.
Antidepressants and other medication
The total cost of antidepressants prescribed and other included medication costs were calculated using daily dose information and costs of the generic drug as listed in the British National Formulary.
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Secondary care service Unit costs for all hospital services were taken from the National Schedule of NHS Reference costs for 2011/12.
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Primary care services and social care and voluntary services For NHS primary care services, social workers, and support workers costs contained in the Unit Costs of Health and Social Care and NHS Reference costs were used.
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Calculation of Quality Adjusted Life Years (QALYs) QALYs were calculated using the area under the curve approach after the health states from the EQ-5D were converted into utility scores using responses from a representative sample of adults in the UK. 11 It was assumed that changes in utility score over time followed a linear path. 12 QALYs in the second year were discounted at a rate of 3·5% as recommended by NICE and all analyses were adjusted for baseline utility scores to take into consideration the impact any baseline differences will have on the area under the curve. 6, 13 Data analysis For base case calculations, complete case analysis was used, with the impact of missing data explored in sensitivity analyses. All analyses were carried out on an intention to treat basis using STATA (www.stata.com ).
Resource use
Resource use by the study participants is reported descriptively for each group at 86 weeks as mean use and percentage of the group who had at least one contact. No statistical comparisons between use of services are made to avoid problems associated with multiple testing, and because the focus of the economic evaluation is on cost and cost-effectiveness.
Difference in costs and QALYs
A number of tests for differences in costs at 86 weeks between randomised groups were completed:
These were analysed using linear regression models with the following pre-specified covariates: baseline costs (total cost over the previous three months), region (East Anglia, North London, North West), behavioural disorder at baseline (measured using the K-SADS-PL), and antidepressant use at baseline. The validity of the results were confirmed using bias-corrected, non-parametric bootstrapping (repeat re-sampling).
14 Despite the skewed nature of cost data, this approach is recommended to enable inferences to be made about the arithmetic mean.
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Cost-effectiveness analyses For cost-effectiveness, analysis moves from considering differences in costs and outcomes in terms of statistical significance to analysing costs and outcomes together in a decision-making context 16 . The cost-effectiveness analysis, undertaken using QALYs calculated from the EQ-5D measure of health-related quality of life, was completed for the following comparisons:
Initially, incremental cost-effectiveness ratios (ICERs) were calculated, which are the difference in mean cost divided by the difference in mean effect. 17 Because ICERs are calculated from four sample means and are therefore subject to statistical uncertainty, 5000 re-samples (bootstrapping) from the cost and outcomes data were used to generate a distribution of mean costs and effects. 15 These distributions were plotted onto the costeffectiveness plane for interpretation. Replications that fall in the South-West quadrant of the plane suggest that the intervention is less costly and less effective than the comparator, and those that fall in the South-East quadrant suggest that the intervention is less costly and more effective than the comparator. Replications in the North-West quadrant suggest the intervention is more costly and less effective than the comparator, while those in the NorthEast quadrant suggest the intervention is more costly and more effective than the comparator.
The bootstrapped distributions were also used to calculate the probability that each of the treatments is the optimal choice, subject to a range of possible maximum values (the ceiling ratio, λ) that a decision-maker might be willing to pay for a unit improvement in outcome. To explore the uncertainty that exists around estimates of mean costs and effects as a result of sampling variation and uncertainty regarding the maximum value of λ, costeffectiveness acceptability curves (CEACs) are presented by plotting these probabilities for a range of possible values of the ceiling ratio (λ). 18 All analyses used baseline costs, region, and behavioural disorder at baseline as covariates.
Sensitivity analyses
A number of sensitivity analyses were carried out to test the robustness of the assumptions made:
1. The cost of sessions offered but not attended was explored by increasing the cost from the assumption of zero applied in the main analysis (which assumes professionals are able to make use of the time available to undertake alternative tasks) to 50% of the cost of a session (which assumes professionals make some use of the time available, but not all). Data were calculated as the number of sessions offered minus the number of sessions attended, which may not be exactly equivalent to the number of DNAs (did not attend) as sessions may have been offered but cancelled or rearranged. This analysis should therefore be interpreted with caution. 2. The impact of missing data was considered using multiple imputation of missing values. 3. Due to the variation in the timing of follow-up, cost per week was calculated and analysed.
Economic evaluation results
Data completeness
At 86 weeks, full CA-SUS service use data was available for 94 participants (61%) in the CBT group, 91 (58%) in the STPP group, and 92 (59%) in the BPI group, which was 60% of the total number randomised.
Outliers
The cost data were examined to consider the impact of highly influential observations, defined by Weichle et al 19 as those whose exclusion result in major changes in the results. Two observations were identified as above the 99 th percentile for total costs, but only one of these would have increased parameter estimates by a factor of 1.4. Therefore this one observation was removed from the main analysis as recommended.
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Resource use All resources used over the 86-week follow-up period are summarised by group in Table A11 .
Trial treatment
For the sample of participants with full service use information, the average number of treatment sessions attended by the young people was 7·97 in the BPI group, 9·73 in the CBT group and 13·85 in the STPP group. The numbers differ slightly from those reported in the main paper because they are the results for the sub-sample of participants for whom we had full service use data. On average, the number of sessions attended was lower than the number of sessions planned (BPI 12 sessions, CBT 20 sessions, STPP 28 sessions).
Other health and social services
Overall there was little difference between randomised groups in levels of service use over the 86 week follow-up (see Table A11 ). Levels of mental health admissions were low (less than 2%) across all randomised groups. There were slight variations in non-mental health admissions, with 13% of the STPP group being admitted compared to 8% in the BPI group and 5% in the CBT group. Overall up to a fifth of participants had a nonmental health admission. Accident and emergency attendances were not uncommon (BPI 23·40%, CBT 12·63%, STPP 19·57%), but average levels of attendance were less than one contact in each group.
GPs were the most widely used service, accessed by 66%, 72%, and 64% of participants in the BPI, CBT, and STPP groups, respectively. Use of community mental health services, excluding the trial interventions, was highest in the BPI group (46% of BPI participants) compared to 38% and 29% of the CBT and STPP groups, respectively. Rates of social services contacts were also highest in the BPI group.
Antidepressant medication
Over the course of the study, patients were allowed to receive an SSRI in addition to psychological treatment if they met National Institute of Health and Care Excellence guidelines for combined treatment to aid clinical remission by end of treatment. The proportion of participants prescribed antidepressant medication at any point over the 86-week follow-up was around 30% in each group. 
Total cost
Treatment costs
On average the cost of the trial interventions was lowest for CBT (£904·57) and highest for STPP (£1396·72), with BPI costing £1292·91. These differences reflect variation in the number and duration of treatment sessions and the cost of the professionals providing the therapy.
Total costs over follow-up
The broadly similar levels of service use reported in Table A11 translated into similar total health, social care and education costs per participant over the 86 week follow-up across the three groups: £1368·04 in the BPI group, £1459·26 in the CBT group, and £1668·51 in the STPP group. Including the cost of the trial interventions generated total costs per participant over the 86 week follow-up of £2678·39 for BPI, £2379·01 for CBT, and £3081·70 for STPP (see Table A12 ).
The results of the between group comparisons, detailed in Table A13 , show that there were no significant differences in costs between groups. Bootstrapped confidence intervals were similar to those calculated from the linear regression models so are not presented here. Health-related quality of life EQ-5D scores at baseline and all follow-up points are detailed in Table A14 . Utility scores were generally higher in the CBT group compared to BPI and STPP, where a higher score denotes higher levels of health-related quality of life. However, differences were small and at the 86 week follow-up, scores were marginally higher in the BPI group followed by the STPP group. The QALYs show very little between group differences: BPI group 1.241 QALYs, CBT group 1·228 QALYs, and STPP 1·246 QALYs. There were no significant between group differences in QALYs as shown in Table A15 . Cost-effectiveness analysis CBT v BPI For the CBT versus BPI comparison, CBT is less costly but slightly less effective in terms of QALYs than BPI. As a result, the replications produced in the scatterplot in Figure A1 are mainly in the SouthWest and South-East quadrants reflecting lower costs in the CBT group (points below the x-axis) and the very small difference in outcomes between the two groups (points evenly spread across the y-axis). The cost-effectiveness acceptability curve (CEAC) in Figure A2 shows that for all levels of willingness to pay per QALY there is a higher probability that CBT is more cost-effective than BPI. Figure A3 . The majority are in the North-East and North-West quadrants, reflecting the higher costs in the STPP group (points above the x-axis). The CEAC in Figure A4 shows that there are no willingness to pay values where the probability of STPP being cost-effective compared to BPI is greater than 23%, within the £20,000-£30,000 ceiling level of willingness to pay considered acceptable by NICE 6 .
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CBT v STPP
Comparing the two intensive psychological treatments, CBT and STPP, total costs per participant over the 86 week follow-up were on average £703 lower in the CBT group and outcomes 0·02 QALYs worse. As a result, the replications in the scatterplot in Figure A5 are mostly in the South-West quadrant. The CEAC shown in Figure A6 suggests that the probability that CBT is cost-effective compared to STPP for all willingness to pay values is greater than 50%. 
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CBT v STPP v BPI
The three interventions were compared head to head in a three-way comparison. The CEACs in Figure  A7 show that for all values that a decision maker might be willing to pay for a QALY, CBT has the highest probability of being cost-effective. The results of the sensitivity analyses are detailed in Tables A16 and A17 . Multiple imputation did not alter the direction of the differences in cost, nor did re-analysis using cost per week rather than cost over the entire follow-up period. Including an estimate of the cost of sessions that were scheduled but which the young person did not attend, however, altered the order between the three interventions.
For the sample with full economic data, the average number of sessions that were offered but were not attended were three in the BPI group, 14 in the CBT group, and six in the STPP group. The inclusion of the cost of these sessions (at 50% of the cost of a full session) resulted in the average cost of CBT (£3,050) becoming more expensive than the BPI mean cost (£2,939), with STPP remaining the most costly group (mean cost £3,364).
Whilst there remain no statistically significant differences in cost between the groups, this change in direction impacts upon the cost-effectiveness analyses for the comparison of CBT and BPI. Figure A8 shows the scatter plot for this comparison; the majority of the replications are in the North-East and North-West quadrants denoting higher costs in the CBT group (points above the x-axis). The very similar outcomes mean that the CEAC in Figure A9 suggests that the probability that CBT is costeffective compared to BPI is less than 50% for all values a decision maker might be willing to pay for a QALY. Figure A10 shows a head to head comparison of all three groups in terms of cost-effectiveness and including a cost for sessions missed. It demonstrates that there is a higher probability of BPI being cost-effective compared to CBT and STPP, for all values of willingness to pay. 
Moderation of treatment effects
Little is understood regarding factors that may influence treatment response in depressed adolescents. This study included 2 putative cognitive processes that the literature suggests may moderate therapeutic response to different psychological treatments. These are: i) Individual differences in self-reported ruminative thinking whilst depressed. A ruminative response style is defined as persistently brooding or dwelling on current depressive thoughts and feelings, often to the exclusion of other themes in the patient's life. 20 ii) The quality of predominant depressive experiences, which is, defined as possessing a thinking style (dependent or self-critical) likely to predispose or be associated with depressive illness but not synonymous with a pattern of symptoms.
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Ruminative response style
Rumination is the compulsively focused attention on the symptoms of one's distress, and on its possible causes and consequences, as opposed to its solutions. 22 Rumination is similar to worry except rumination focuses on bad feelings and experiences from the past, whereas worry is concerned with potential bad events in the future. 23 Both rumination and worry are associated with clinical anxiety and depression. 23 Rumination has been widely studied as a cognitive vulnerability factor for depression, however its measures have not been unified. In the Response Styles Theory proposed by NolenHoeksema 23 rumination is defined as "compulsively focused attention on the symptoms of one's distress, and on its possible causes and consequences, as opposed to its solutions". Because the 
Depressive experiences style
Both theoretical assumptions and empirical findings suggest that adult patients with clinical depression may be characterized by a cognitive styles of excessive preoccupation with relatedness (principally focused on disappointment with relationships) and self-definition or identity (principally focused on self-criticism). 24 As such individuals with depression may be predominantly troubled by one of the following issues which have been shown as 2 independent factors in the depression experiences style self report scale: i) High concerns about the quality of interpersonal relatedness with feelings of emptiness and loneliness, and intense fears of being abandoned and left unprotected. Termed dependent/relatedness ii) Possessing an extremely self-critical attitude together with feelings of worthlessness, guilt, failure, and self-blame. Termed self-critical/identity
Moderator effects on the primary outcome were investigated by adding an interaction between the moderator variable and treatment allocation to the primary analysis model. Table 16 gives the estimates of the treatment by moderator effect for each of the moderator hypotheses proposed in the methods section (see Chapter 7 for details of measures and chapter 8 for analytic strategy and hypotheses). A negative estimate in this table indicates that a higher score of the moderator lowered the MFQ for the treatment relative to the comparator, that is an increase in the beneficial treatment effect.
First, we hypothesized that young people with elevated dependency sub scale sum scores on the Depressive Experiences Questionnaire (DEQ) would have greater reduction in MFQ if they received STPP rather than BPI or CBT treatment than those with lower scores. Before 36 weeks the direction of the effect was consistent with our hypothesis but this was not statistically significant (p=0.168). After 36 weeks there was clearly no evidence of an effect (p=0.918).
Secondly, we hypothesized that young people with elevated self-critical sun scale sum scores on the Depressive Experiences Questionnaire would have a better response if they received CBT rather than either BPI or STPP treatment. The direction of the effect was consistent with our hypothesis both before and after 36 weeks but with a significant trend by 36 weeks (0.053) but no evidence subsequently (p=0.384).
Finally, we hypothesized that higher total scale scores for rumination response style of thinking when depressed (RSS) would show a better treatment response for CBT than BPI or STPP treatment. There was no evidence for such an effect either before (p=0.671) or after (p=0.976) thirty-six weeks
